The impact of highly active antiretroviral therapy (HAART) can be evaluated using indicators, such as rates of opportunistic infections, hospitalizations by cause of infection, and associated death.

Gilead's HIV drug lenacapavir earns FDA priority review after strong trial results, with the company planning to double U.S.